Regarding the application of biosimilars in peripheral stem cells mobilisation, our group reported their experience on the use of Plerixafor in 28 patients treated with the G-CSF originator or with G-CSF biosimilar (Tevagrastim) in patients with lymphoma or myeloma candidate to autologous stem cell transplantation. This evidence concerns the gene CSF3 and plasma cell myeloma.